Thomas Laver

Senior Lecturer in Human Genetics

University of Exeter
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

A substantial proportion of individuals with a well-defined monogenic disorder remain without a genetic diagnosis. Low-level mosaic pathogenic variants are increasingly recognised as an underappreciated cause of monogenic disease but are technically challenging to detect, particularly in organ-specific conditions when affected tissue is inaccessible. We systematically investigated low-level mosaic variants in individuals with congenital hyperinsulinism (CHI: n=1,252) or neonatal diabetes (NDM: n=312), two opposing pancreatic disorders of insulin secretion. We screened for established pathogenic variants with variant allele fraction (VAF) <8% in dominant CHI ( ABCC8 , GCK , GLUD1 , HK1 ) or dominant NDM ( ABCC8 , KCNJ11 , INS ) genes in targeted next generation sequencing (tNGS) data using Mutect2. This called 40 variants across the four genes in 39 individuals with CHI. No candidate variants were found in the NDM cohort. Orthogonal validation of 35 variants using TaqMan-based droplet digital PCR (ddPCR) confirmed 26/35 variants. The median VAF for confirmed variants was 3.6% (1.1–7.8%), while false positives (9/35) predominantly had a VAF <1% with some overlap in VAF with true positives. This study shows that disease-causing low-level mosaic variants in dominant CHI genes can be detected in blood using tNGS but require orthogonal validation. These results provide a framework to improve diagnostic yield in organ-specific conditions where mosaic variants may represent an important missed cause of disease.

Year:

2026

Background We recently reported non-coding variants in a cis -regulatory element of the beta-cell disallowed gene hexokinase 1 ( HK1 ) as a novel cause of congenital hyperinsulinism. These variants lead to a loss of repression of HK1 in pancreatic beta-cells, causing insulin secretion during hypoglycaemia. In this study, we aimed to determine the prevalence, genetics, and phenotype of HK1 -hyperinsulinism by screening a large international cohort of patients living with the condition. Methods We screened the HK1 cis -regulatory region in 1761 probands with hyperinsulinism of unknown aetiology who had been referred to one of three large European genomics laboratories. Results We identified a HK1 variant in 89/1761 probands (5%) and 63 family members. Within the Exeter HI cohort, these variants accounted for 2.8% of all positive genetic diagnoses ( n = 54/1913) establishing this as an important cause of HI. Individuals with a disease-causing variant were diagnosed with hyperinsulinism between birth and 26 years (median: 7 days) with variable response to treatment; 80% were medically managed and 20% underwent pancreatic surgery due to poor response to medical therapy. Glycaemic outcomes varied from spontaneous remission to hypoglycaemia persisting into adulthood. Eight probands had inherited the variant from a parent not reported to have hyperinsulinism (median current age: 39 years), confirming variable penetrance. Two of the 23 novel HK1 variants allowed us to extend the minimal cis -regulatory region from 42 to 46 bp. Conclusions Non-coding variants within the HK1 cis -regulatory region cause hyperinsulinism of variable severity ranging from neonatal-onset, treatment-resistant disease to being asymptomatic into adulthood. Discovering variants in 89 families confirms HK1 as a major cause of hyperinsulinism and highlights the important role of the non-coding genome in human monogenic disease.

Year:

2025

Introduction Congenital hyperinsulinism (HI) is characterized by inappropriate insulin secretion from the pancreatic beta-cells which causes severe hypoglycemia. Copy number variants (CNVs) encompassing multiple genes (contiguous gene CNVs) can cause syndromic forms of HI although they are not typically screened for during routine genetic testing for this condition. We aimed to assess the prevalence of disease-causing contiguous gene CNVs in a cohort of individuals referred for HI genetic testing. Methods Our cohort consisted of 3,763 individuals, of which 1,916 had received a genetic diagnosis for their HI and 1,847 were genetically unsolved following routine testing. We screened for 6 different contiguous gene CNVs using next-generation sequencing data from all individuals in the genetically unsolved cohort and searched for patients in our solved cohort who had already been found to have one of these CNVs. Results We identified a contiguous gene CNV affecting 5 of the 6 genomic loci in 53 probands; 28 from the solved cohort and 25 from the genetically unsolved cohort. Variants on the X chromosome were most common, being detected in 24/53 children. Overall, these variants represented 2.7% (53/1,941) of genetic diagnoses, which is similar to the prevalence of variants in other commonly screened HI genes. Discussion These results confirm that contiguous gene CNVs are an important cause of HI which should be included in standard gene panel testing processes as this will improve pick-up rates for genetic diagnoses in HI.

Year:

2025

Context Hyperinsulinemic hypoglycemia (HI) can be the presenting feature of Kabuki syndrome (KS), which is caused by loss-of-function variants in KMT2D or KDM6A. As these genes play a critical role in maintaining methylation status in chromatin, individuals with pathogenic variants have a disease-specific epigenomic profile—an episignature. Objective We evaluated the pathogenicity of 3 novel partial KDM6A duplications identified in 3 individuals presenting with neonatal-onset HI without typical features of KS at the time of genetic testing. Methods Three different partial KDM6A duplications were identified by routine targeted next-generation sequencing for HI and initially classified as variants of uncertain significance (VUS) as their location, and hence their impact on the gene, was not known. Whole-genome sequencing (WGS) was undertaken to map the breakpoints of the duplications with DNA methylation profiling performed in 2 individuals to investigate the presence of a KS-specific episignature. Results WGS confirmed the duplication in proband 1 as pathogenic as it caused a frameshift in the normal copy of the gene leading to a premature termination codon. The duplications identified in probands 2 and 3 did not alter the reading frame, and therefore their significance remained uncertain after WGS. Subsequent DNA methylation profiling identified a KS-specific episignature in proband 2 but not in proband 3. Conclusion Our findings confirm a role for KDM6A partial gene duplications in the etiology of KS and highlight the importance of performing in-depth molecular genetic analysis to properly assess the clinical significance of VUS' in the KDM6A gene.

Year:

2025

Non-coding variants in the promoter region of SLC16A1 , a beta-cell-disallowed gene encoding Monocarboxylate Transporter 1 (MCT1), cause exercise-induced hyperinsulinism (EIHI). These variants are thought to cause aberrant expression of MCT1 in pancreatic beta-cells, enabling pyruvate uptake during exercise which triggers inappropriate insulin secretion. We identified a 94-bp deletion in the SLC16A1 promoter in 37 individuals from 11 families with childhood- or adult-onset hyperinsulinemic hypoglycemia (HI). Patient pancreatic tissue showed elevated MCT1 expression, confirming the disease mechanism. To investigate the functional impact of the deletion, we generated induced pluripotent stem cells from an affected individual and differentiated them into pancreatic stem-cell-derived islets (SC-islets). These patient-derived SC-islets showed increased SLC16A1 gene and protein expression in vitro and failed to repress MCT1 expression following in vivo maturation in immunocompromised mice. Ex vivo pyruvate stimulation selectively triggered insulin secretion in variant grafts, effectively recapitulating the EIHI phenotype. In individuals with the deletion, the hypoglycemia was triggered by physical activity, carbohydrate-rich meals, and fasting, with considerable variability in age at onset and clinical severity. These findings broaden the phenotypic spectrum of SLC16A1 promoter variants and support the inclusion of SLC16A1 promoter analysis in the genetic evaluation of individuals with unexplained HI across all ages.

Year:

2025

Aims/hypothesis Accurate interpretation of loss-of-function (LOF) variants in MODY genes is essential for diagnosis but remains challenging, particularly for variants predicted to escape nonsense-mediated decay (NMD). We aimed to systematically evaluate the pathogenicity of LOF variants, stratified by NMD-triggering and NMD-escape status, across all known MODY genes. Methods We analysed ultra-rare LOF variants (minor allele frequency 800,000 population controls. Individuals presented with diabetes at a median age of 19 years, had median BMI of 22.9 kg/m 2 , were negative for islet autoantibodies, and had low type 1 diabetes genetic risk scores. Compared with INS missense MODY, diagnosis occurred ∼10 years later. Protein modelling suggested that INS NMD-escape variants produce aberrant proinsulin molecules with unpaired B chain cysteines, leading to milder misfolding. Conclusions/interpretation The pathogenicity of LOF variants in MODY genes depends on gene context and NMD status. Heterozygous NMD-escape LOF variants in INS are a novel cause of MODY. These findings provide systematic gene-level evidence to inform variant interpretation guidelines and improve the accuracy of MODY diagnosis in clinical practice. Research in Context What is already known about this subject? Interpretation of loss-of-function (LOF) variants is complex and strongly influenced by predicted NMD status. Current evidence for LOF variants in MODY genes is mainly based on case reports. Systematic genetic evidence is needed to improve diagnosis and to inform gene-specific variant interpretation guidelines. What is the key question? Do NMD-triggering and NMD-escape LOF variants contribute to MODY across all known MODY genes? What are the new findings? Heterozygous NMD-escape LOF variants in INS are a novel cause of MODY. Heterozygous LOF variants in ABCC8 and KCNJ11 are not enriched in MODY. Enrichment of NMD-triggering and NMD-escape LOF variants differs across MODY genes, clarifying underlying mechanisms and supporting gene-specific interpretation. How might this impact on clinical practice in the foreseeable future? These results improve the accuracy of MODY diagnosis by providing robust evidence for variant interpretation and supporting gene-specific clinical guidelines.

Year:

2025

Context Diagnosing Maturity-Onset Diabetes of the Young (MODY) is clinically important for treatment and prognosis. However, phenotype-based studies of MODY are prone to ascertainment bias, limiting accurate estimates of its population prevalence and phenotypic spectrum. Objective To apply a genotype-first approach to determine the population prevalence, penetrance, and all-cause mortality associated with MODY. Methods We analysed exome sequencing and clinical data from 454,275 UK Biobank participants to identify pathogenic variants in 10 established MODY genes. We assessed variant prevalence, age-dependent diabetes penetrance, and all-cause mortality by genetic aetiology over a mean follow-up of 13.4 years. Results Pathogenic MODY variants were present in 1 in 1,052 individuals and accounted for 1.48% of diabetes cases diagnosed before age 40. GCK variants were the most frequent (1 in 2,787), demonstrating high penetrance (mean HbA1c 8.8 mmol/mol higher; 94.5% with prediabetes or diabetes) but no significant association with all-cause mortality ( P =0.09). Variants in other MODY genes showed lower penetrance, with 12% of carriers developing diabetes by age 40 and 31.6% by age 60 and showed no increase in all-cause mortality ( P =0.89). Penetrance varied by genetic aetiology, with HNF1A showing the highest penetrance and PDX1 , NEUROD1 , and RFX6 the lowest. Parental history of diabetes and polygenic risk for type 2 diabetes were important modifiers of penetrance (Hazard ratios 2.54 and 1.52 respectively, P <3.9×10 −3 ). Conclusions This large-scale genotype-first study provides novel insights into MODY in the population. These findings have broad implications for genetic counselling, personalised treatment strategies, and healthcare resource allocation.

Year:

2025

An accurate genetic diagnosis of Maturity-Onset Diabetes of the Young (MODY) is critical for personalised treatment. To avoid misdiagnosis, only genes with strong evidence of causality must be tested. Heterozygous variants in NEUROD1 , PDX1 , APPL1 , and WFS1 have been implicated in MODY, but strong genetic evidence supporting causality is lacking. We therefore assessed their existing genetic evidence and performed the gene-level burden tests in a large MODY cohort, alongside two established MODY genes as positive controls ( HNF1A -high penetrance, RFX6 -low penetrance). The first reported MODY-associated variants in NEUROD1 , PDX1 , APPL1 , and WFS1 were 0.06). In contrast, variants in NEUROD1 and PDX1 were enriched, albeit at levels comparable to RFX6 . Multiple sensitivity analyses corroborated these findings. In summary, rare heterozygous variants in NEUROD1 and PDX1 are low-penetrance causes of MODY, while those in APPL1 and WFS1 lack robust genetic evidence for causality and should not be included in MODY testing panels. Article highlights Why did we undertake this study? Testing genes with limited evidence of causality risks misdiagnosis of MODY. What is the specific question(s) we wanted to answer? Do rare variants in PDX1 , NEUROD1 , APPL1 , and WFS1 cause MODY? What did we find? Rare damaging variants in APPL1 and WFS1 are not enriched in a MODY cohort, but those in PDX1 and NEUROD1 are, at a level similar to low-penetrance MODY genes. What are the implications of our findings? PDX1 and NEUROD1 should be included in MODY gene panels, while heterozygous APPL1 and WFS1 variants should not be reported as causes of MODY.

Year:

2025

Year:

2024

Persistent congenital hyperinsulinism (HI) is a rare genetically heterogeneous condition characterised by dysregulated insulin secretion leading to life-threatening hypoglycaemia. For up to 50% of affected individuals screening of the known HI genes does not identify a disease-causing variant. Large deletions have previously been used to identify novel regulatory regions causing HI. Here, we used genome sequencing to search for novel large (>1 Mb) deletions in 180 probands with HI of unknown cause and replicated our findings in a large cohort of 883 genetically unsolved individuals with HI using off-target copy number variant calling from targeted gene panels. We identified overlapping heterozygous deletions in five individuals (range 3–8 Mb) spanning chromosome 20p11.2. The pancreatic beta-cell transcription factor gene, FOXA2 , a known cause of HI was deleted in two of the five individuals. In the remaining three, we found a minimal deleted region of 2.4 Mb adjacent to FOXA2 that encompasses multiple non-coding regulatory elements that are in conformational contact with FOXA2 . Our data suggests that the deletions in these three children may cause disease through the dysregulation of FOXA2 expression. These findings provide new insights into the regulation of FOXA2 in the beta-cell and confirm an aetiological role for chromosome 20p11.2 deletions in syndromic HI.

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (11)

Timo Otonkoski

University of Helsinki

FINLAND
View details

Sarah Flanagan

Professor of Genomic Medicine and Wellcome Trust Senior Research Fellow

University of Exeter

UNITED KINGDOM
View details

Kashyap A Patel

University of Exeter Medical School

UNITED KINGDOM
View details

James Russ-Silsby

University of Exeter

UNITED KINGDOM
View details

Elisa De Franco

University of Exeter

UNITED KINGDOM
View details

Michael N Weedon

Associate Professor

University of Exeter Medical School

UNITED KINGDOM
View details

Diva D. De Leon

Professor of Pediatrics

University of Pennsylvania

UNITED STATES
View details

Gareth Hawkes

Lecturer in Health Data Science

University of Exeter

UNITED KINGDOM
View details

Indraneel Banerjee

Professor

Manchester University NHS Foundation Trust

UNITED KINGDOM
View details

Rachel Crowley

St. Vincent's University Hospital

IRELAND
View details

Andrew Hattersley

Professor of Molecular Medicine

University of Exeter

UNITED KINGDOM
View details